Venous thromboembolism is comprised of pulmonary embolism and deep venous thrombosis and is associated with significant morbidity and mortality.
All patients admitted for major trauma, surgery or acute medical illness should be assessed for risk of venous thromboembolism and bleeding before starting prophylaxis for venous thromboembolism.
Decision on which type of prophylaxis to be given must be individualized for each patient.
Patients with acute, low-risk pulmonary embolism (PE) can be safely discharged within 2 days of hospitalization and treated with rivaroxaban out-of-hospital with a low incidence of recurrence, findings of the HoT-PE* study showed.
Apixaban slashes the risk of recurrent venous thromboembolism (VTE) by 90 percent in cancer patients compared with the low-molecular-weight heparin (LMWH) dalteparin, with no increase in major bleeding risk, according to the ADAM VTE study presented at ASH 2018.
Use of direct-acting oral anticoagulants (DOACs) in patients with cancer and venous thromboembolism (VTE) results in only two episodes of clinically significant bleeding and no episodes of recurrent VTE, according to the results of a single-centre, retrospective, observational study.
Aspirin is as effective as rivaroxaban in the prevention of symptomatic venous thromboembolism following total hip or total knee arthroplasty in patients who have already received 5 days of rivaroxaban prophylaxis, according to a study.
Tailored therapy duration with elastic compression stockings based on a patient’s signs and symptoms was noninferior to the standard therapy duration of 24 months in preventing post-thrombotic syndrome (PTS), according to the IDEAL-DVT* study.
The noninferiority of edoxaban compared with dalteparin in preventing recurrent venous thromboembolism (VTE) and major bleeding in patients with cancer highlights edoxaban as a potential alternative to low molecular weight heparin (LMWH) in this group of patients, suggests results of the Hokusai VTE-Cancer Study presented at ASH 2017.
Treatment with direct-acting oral anticoagulants (DOACs) was not associated with increased risks of major bleeding or deaths from any cause within 90 days of therapy initiation, when compared with warfarin in adults with newly diagnosed venous thromboembolism (VTE), according to a large real-world study.
Rosuvastatin led to improved coagulation profile, in particular lower levels of factor VIII procoagulant activity (VIII:C), among patients who had venous thrombosis (VT) previously, suggesting that statins could reduce the risk of recurrent VT, according to a study presented at the ISTH 2017 Congress in Berlin, Germany.
Elderly persons (≥75 years) on aspirin-based antiplatelet therapy without routine proton-pump inhibitor (PPI) use have a higher long-term risk of major bleeding, in particular upper gastrointestinal (GI) bleeding which is often more disabling or fatal than in younger persons, according to the OXVASC* study.
Elderly cancer patients on anticoagulant therapy are at least nine times more likely to die within 7 days after a major bleeding event than after a venous thromboembolism (VTE) recurrence, suggests a study presented at the EHA Congress 2017 in Madrid, Spain.
Higher values of plasma aldosterone concentration (PAC) show a robust association with some metabolic variables, including triglycerides, urinary albumin excretion (UAE), carotid intima-media thickness (cIMT), worse ankle-brachial index (ABI) and major prevalence of carotid plaques, a recent study has shown.
No association exists between a vegan diet and lower blood pressure (BP) measurements as compared with omnivorous alternatives, a study has found. The effect of a vegan diet in adults is similar to that by portion-controlled diets and those recommended by medical societies.
Patients with greater ischaemia who underwent positron emission tomography (PET) myocardial perfusion imaging (MPI) have better survival with early revascularization, reports a study. Exploratory analyses reveal a lower threshold than that previously reported for single-photon emission computed tomography (SPECT).